Tamoxifen associated fatty liver
Conditions
Interventions
Experience group:Decoction of Chinese Medicine
control group :essentiale
Experience group:Diet and exercise guidance
Sponsors
Beijing Hospital of TCM Affiliated to Capital Medical University
Eligibility
Sex/Gender
Female
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: 1. Women with breast cancer who were diagnosed with fatty liver after endocrine therapy (tamoxifen); 2. The KPS score over 70 points; 3. Aged less than 60 years; 4. According to the "guiding principle" Chinese medicine clinical research to determine liver stagnation and spleen deficiency, phlegm and blood stasis; 5. The expected survival of more than 1 years; In the group can continue to endocrine therapy to the end of the subject; 6. The blood and heart, lung, liver, kidney and other organs of normal function; 7. Voluntarily participated in this study, good compliance, and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Does not meet the inclusion criteria of the above; 2. Endocrine therapy prior to the merger fatty liver, hyperlipidemia and other liver diseases; 3. Patients with diabetes; 4. Drinking history and drinking alcohol equivalent is greater than 70g / week; 5. Fails to complete the treatment of endocrine therapy, can not determine the efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom score;Controlled attenuation parameter;blood lipid level;liver function test; | — |
Countries
China
Contacts
Public ContactTANG Wujun
Beijing Hospital of TCM Affiliated to Capital Medical University
Outcome results
None listed